Company strengthens AI and technology leadership as it advances next-generation precision oncology platform CHICAGO, IL – January 27, 2026 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today announced the appointment of Senthil Periaswamy,…
Vincent Reid, MD, FACS, Chairman of Surgery and Medical Director at the Hall Perrine Cancer Center, Mercy Cedar Rapids, to share clinical experience and real-world case studies using TumorSight™ Viz CHICAGO, IL and EXTON, PA – December 2, 2025 –…
National feature spotlights TumorSight™ Viz’s clinical use at Mercy Cedar Rapids and initiative with NVIDIA advancing AI-powered precision breast cancer care CHICAGO, IL – October 27, 2025 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and…
By Stacey Stevens, President & CEO, SimBioSys Every October, pink ribbons remind us of how far we’ve come in the fight against breast cancer — and how far we still have to go. Despite remarkable progress in awareness, screening, and…
Commercial partnership expected to accelerate adoption of SimBioSys’ AI-powered surgical visualization platform following recent FDA clearance of TumorSight Viz 1.3 CHICAGO, IL and EXTON, PA, August 27, 2025 – SimBioSys®, a clinical AI company leveraging spatial biophysics to drive precision…
Latest release introduces industry-leading AI performance, optimized workflow integration, and enhanced surgeon usability to streamline imaging-to-intervention planning CHICAGO, July 9, 2025 /PRNewswire/ — SimBioSys®, a clinical AI company leveraging spatial biophysics to drive precision in breast cancer treatment, today announced its third…
Our presence at ASBrS will be an excellent opportunity to demonstrate how this synergy has the potential to benefit surgeons and patients by providing a clearer understanding of complex cancer surgeries before the first incision is made. EXTON, Pa. &…
PhenoScope™, SimBioSys’ powerful proprietary technology and service, can analyze vast fields of multi-modal data seamlessly, generating novel insights, including unique spatial biophysical insights in a 4-dimension space, for cancer drug discovery and development which are not apparent by looking at…
Metabolic reprogramming and tumor angiogenesis are two tightly linked hallmarks of cancer. Regions of high metabolic activity within a tumor can become hypoxic or nutrient starved, eliciting a cascade of pro-angiogenic signals that can lead to increased tumor perfusion and in turn greater metabolic…
As new antibody drug conjugates are developed, the question of which specific patients will respond to these therapies remains. This work develops a spatial PK/PD model for the antibody drug conjugate trastuzumab emtansine, T-DM1, and explores the relationship between HER2 (target) expression and other individual features of the tumor microenvironment…
SOLUTIONS
- TumorSight Viz
- TumorSight RISK
- PhenoScope
RESOURCES
©SimBioSys